Methods of treating glutathione deficiencies and deficiencies in glutathione synthetase activity

Abstract

Glutathione deficiencies and deficiencies in glutathione synthetase activity, and therapeutic methods for the treatment thereof.

Claims

1. A method of treating a glutathione deficiency in a human patient in need thereof comprising administering to the patient a therapeutically effective amount from 15 to 50 mg/day of L-ergothioneine or a pharmaceutically acceptable salt thereof, wherein the patient is suffering from GSH RBC levels ≤1,200 μmol/L.

2. A method of treating a glutathione synthetase deficiency causing hemolytic anemia in a human patient in need thereof comprising administering to the patient a therapeutically effective amount from 15 to 50 mg/day of L-ergothioneine or a pharmaceutically acceptable salt thereof, wherein the patient is suffering from GSH RBC levels ≤1,200 μmol/L.

3. The method of claim 2, wherein the patient has glutathione synthetase deficiency causing hemolytic anemia (OMIM 231900).

4. A method of treating a generalized glutathione synthetase deficiency with 5-oxoprolinuria in a human patient in need thereof comprising administering to the patient a therapeutically effective amount from 15 to 50 mg/day of L-ergothioneine or a pharmaceutically acceptable salt thereof, wherein the patient is suffering from GSH RBC levels ≤1,200 μmol/L.

5. The method of claim 4, wherein the patient is suffering from glutathione synthetase deficiency with 5-oxoprolinuria (OMIM 266130).

6. The method of claim 1, wherein the glutathione deficiency is characterized by a reduction in Nrf2 regulated genetic activity.

7. The method of claim 2, wherein the glutathione deficiency is characterized by a reduction in Nrf2 regulated genetic activity.

8. The method of claim 7, wherein the patient has glutathione synthetase deficiency causing hemolytic anemia (OMIM 231900).

9. The method of claim 4, wherein the glutathione deficiency is characterized by a reduction in Nrf2 regulated genetic activity.

10. The method of claim 9, wherein the patient is suffering from glutathione synthetase deficiency with 5-oxoprolinuria (OMIM 266130).

11. The method of claim 1, wherein the therapeutically effective amount comprises about 20 or 25 mg/day of L-ergothioneine or a pharmaceutically acceptable salt thereof.

12. The method of claim 1, wherein the L-ergothioneine is administered as an oral dosage form comprising from 15 to 50 mg of L-ergothioneine.

13. The method of claim 1, wherein the L-ergothioneine is administered as an oral dosage form comprising about 20 mg or 25 mg of L-ergothioneine.

14. The method of claim 1, wherein the L-ergothioneine comprises 0% D-ergothioneine, 0% nucleic acids, 0% amino acids, and less than 2% total impurities.

15. The method of claim 1, wherein the L-ergothioneine is administered in the form of a tablet, capsule, powder sachet, or liquid.

16. The method of claim 1, wherein the patient is suffering from one or a combination of plasma levels of: a) reduced glutathione (GSH)≤3.8, 3.5, or 3.2 μmol/L; b) oxidized glutathione (GSS)≤0.160, 0.130, or 0.100 μmol/L; and/or c) total glutathione (GSH+GSS)≤3.8, 3.5, or 3.2 μmol/L.

17. The method of claim 1, wherein the patient is suffering from one or a combination of: a) lack of energy; b) joint and muscle aches and pains; c) foggy brain; d) low immunity; and/or e) poor sleep.

18. The method of claim 1, wherein the patient is suffering from one or a combination of: a) anemia; b) metabolic acidosis; c) frequent infections; d) seizures, Alzheimer's disease, or Parkinson's disease; e) ataxia; f) liver disease; and/or g) heart attack or stroke.

Description

BRIEF DESCRIPTION OF THE FIGURE

(1) The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the invention and together with the description serve to explain the principles of the invention.

(2) The FIGURE depicts the percent change in baseline in total glutathione in the patients treated in Example 2.

DETAILED DESCRIPTION

Definitions and Use of Terms

(3) As used in the specification and claims, the singular forms a, an, and the include plural references unless the context clearly dictates otherwise. For example, the term “a specification” refers to one or more specifications for use in the presently disclosed methods and systems. “An ingredient” includes mixtures of two or more such ingredients, and the like. The word “or” or like terms as used herein means any one member of a particular list and also includes any combination of members of that list.

(4) When used herein the term “about” will compensate for variability allowed for in the pharmaceutical industry and inherent in products in this industry, such as differences in product strength due to manufacturing variation and time-induced product degradation, as well as differences due to waters of hydration and different salts. The term also allows for any variation which in the practice of good manufacturing practices would allow the product being evaluated to be considered therapeutically equivalent or bioequivalent in humans to the recited strength of a claimed product. In some embodiments the term allows for any variation within 5% or 10% of the recited specification or standard.

(5) As used in this specification and in the claims which follow, the word “comprise” and variations of the word, such as “comprising” and “comprises,” means “including but not limited to,” and is not intended to exclude, for example, other additives, components, integers or steps. When an element is described as comprising one or a plurality of components, steps or conditions, it will be understood that the element can also be described as “consisting of” or “consisting essentially of” the component, step or condition, or the plurality of components, steps or conditions.

(6) “Therapeutically effective amount” means that amount which, when administered to a human for supporting or affecting a metabolic process, or for treating or preventing a disease, is sufficient to cause such treatment or prevention of the disease or supporting or affecting the metabolic process. In any of the embodiments or subembodiments of this invention, a therapeutically effective amount is capable of increasing glutathione concentrations in a patient deficient in glutathione or glutathione synthetase activity.

(7) When ranges are expressed herein by specifying alternative upper and lower limits of the range, it will be understood that the endpoints can be combined in any manner that is mathematically feasible. Thus, for example, a range of from 50 or 80 to 100 or 70 can alternatively be expressed as a series of ranges of from 50 to 100, from 50 to 70, and from 80 to 100. When a series of upper bounds and lower bounds are related using the phase “and” or “or”, it will be understood that the upper bounds can be unlimited by the lower bounds or combined with the lower bounds, and vice versa. Thus, for example, a range of greater than 40% and/or less than 80% includes ranges of greater than 40%, less than 80%, and greater than 40% but less than 80%. Unless otherwise specified by the term “between,” the boundaries of the range (lower and upper ends of the range) are included in the claimed range and can be preceded by the term “about.”

(8) When an element of a process or thing is defined by reference to one or more examples, components, properties or characteristics, it will be understood that any one or any combination of those components, properties or characteristics can also be used to define the matter at issue. This might occur, for example, when specific examples of an element are recited in a claim (as in a Markush grouping), or an element is defined by a plurality of characteristics. Thus, for example, if a claimed system comprises element A defined by elements A1, A2 and A3, in combination with element B defined by elements B1, B2 and B3, the invention will also be understood to cover a system defined by element A without element B, a system in which element A is defined by elements A1 and A2 in combination with element B defined by elements B2 and B3, and all other possible permutations.

(9) “OMIM” refers to the Online Mendelian Inheritance in Man®, An Online Catalog of Human Genes and Genetic Disorders, as Updated on Dec. 30, 2021 (the “OMIM Catalog”). An OMIM number refers to the genetic disorder associated with the number as published in the Catalog on Dec. 30, 2021.

(10) Glutathione synthetase deficiency refers to a condition in which glutathione synthetase activity is impaired, slowed, or lessened, whether by a deficiency in the synthetase enzymes, a defect in synthetase enzyme sequences, a deficiency in synthetase substrates or supporting nutritional co-factors, or any other cause of such impaired activity. A glutathione synthetase deficiency by definition will lead to a glutathione deficiency in the absence of exogenous glutathione supplementation. Conversely, a glutathione deficiency necessarily implies a glutathione synthetase deficiency. Thus, when the term “deficiency” is used herein, it will refer to glutathione deficiency or glutathione synthetase deficiency or both.

(11) Discussion of Principal Embodiments

(12) A first principal embodiment of the invention provides a method a method of treating a glutathione deficiency in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of L-ergothioneine or a pharmaceutically acceptable salt thereof.

(13) A second principal embodiment of the invention provides a method of treating a glutathione synthetase deficiency optionally causing hemolytic anemia in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of L-ergothioneine or a pharmaceutically acceptable salt thereof. In one particular embodiment the patient has glutathione synthetase deficiency causing hemolytic anemia (OMIM 231900).

(14) A third principal embodiment of the invention provides a method of treating a generalized glutathione synthetase deficiency optionally with 5-oxoprolinuria in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of L-ergothioneine or a pharmaceutically acceptable salt thereof. In one particular embodiment the patient is suffering from glutathione synthetase deficiency with 5-oxoprolinuria (OMIM 266130).

(15) A fourth principal embodiment of the invention provides a method of treating a glutathione deficiency characterized by a reduction in Nrf2 regulated genetic activity in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of L-ergothioneine or a pharmaceutically acceptable salt thereof.

(16) A fifth principal embodiment of the invention provides a method of treating a glutathione synthetase deficiency characterized by a reduction in Nrf2 regulated genetic activity optionally causing hemolytic anemia in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of L-ergothioneine or a pharmaceutically acceptable salt thereof. In one particular embodiment the patient has glutathione synthetase deficiency causing hemolytic anemia (OMIM 231900).

(17) A sixth principal embodiment of the invention provides a method of treating a generalized glutathione synthetase deficiency characterized by a reduction in Nrf2 regulated genetic activity optionally with 5-oxoprolinuria in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of L-ergothioneine or a pharmaceutically acceptable salt thereof in one particular embodiment the patient is suffering from glutathione synthetase deficiency with 5-oxoprolinuria (OMIM 266130).

(18) Discussion of Subembodiments

(19) The invention can further be understood with reference to various subembodiments which can modify any of the principal embodiments. It will be understood that these subembodiments can be combined in any manner that is both mathematically and physically possible to create additional subembodiments, which in turn can modify any of the principal embodiments. Generally speaking, in any of the embodiments or subembodiments of the present invention, the patient scan be characterized as suffering from a general loss of appetite, early satiety, altered food preferences, or a combination thereof.

(20) In any of the embodiments of the current invention, the patient can be suffering from one or a combination of plasma levels of:

(21) a) plasma reduced glutathione (GSH)≤3.8, 3.5, or 3.2 μmol/L;

(22) b) plasma oxidized glutathione (GSS)≤0.160, 0.130, or 0.100 μmol/L;

(23) c) plasma total glutathione (GSH+GSS)≤3.8, 3.5, or 3.2 μmol/L;

(24) d) GSH RBC levels ≤1,200 or 1,000 or 800 or 600 or 400 or 250 μmol/L; and/or

(25) e) GSH RBC levels ≤46.9 or 40 or 35 or 30 or 25 or 20 or 15 mg/dL.

(26) Alternatively or in addition, the patient can be characterized by one or more clinical features associated with glutathione deficiencies. Thus, in any of the embodiments of the current invention the patient can be suffering from one or a combination of:

(27) a) lack of energy;

(28) b) joint and muscle aches and pains;

(29) c) foggy brain;

(30) d) low immunity; and/or

(31) e) poor sleep.

(32) In still further embodiments the patient can be suffering from one or a combination of:

(33) a) anemia;

(34) b) metabolic acidosis;

(35) c) frequent infections;

(36) d) seizures, Alzheimer's disease, or Parkinson's disease;

(37) e) ataxia;

(38) f) liver disease; and/or

(39) g) heart attack or stroke.

(40) The L-ergothioneine also can be characterized by its purity or source of production. In any of the embodiments of the present invention, the L-ergothioneine preferably comprises 0% D-ergothioneine, 0% nucleic acids (particularly any thiohistidine derivatives other than L-ergothioneine such as S-methyl-ergothioneine or selenium-containing selenoneine), 0% amino acids, and less than 2% total impurities. The L-ergothioneine can also be characterized by other aspects of its purity, and in various embodiments comprises less than 0.5%, 0.1%, 0.05%, or 0.01%, of the disulfide of L-ergothioneine.

(41) Depending on the purity profile intended, various methods of manufacturing are disclosed in the prior art that can be used to manufacture the L-ergothioneine used in the current invention, including a chemical synthesis process described by Tetrahedron, Vincennes, France in U.S. Pat. No. 8,399,500 B2, a genetically modified S. cerevisiae process described by van der Hoek S A et al. (2019) “Engineering the yeast Saccharomyces cerevisiae for the production of L-()-ergothioneine.” Front Bioeng Biotechnol 7, 262, and an E. coli process described by Nanjing Nutrabuilding Bio-tech Co., Ltd. in WO 2021/102736 A1.

(42) The methods are generally practiced using doses of L-ergothioneine sufficient to increase the concentrations of glutathione or increase glutathione synthetase activity. The dose of L-ergothioneine can vary across a range of suitable doses depending on the health of the subject, the desired response, the dosage form and the route of administration. In a preferred subembodiment when administration is oral, the therapeutically effective amount is from about 15 to about 50 mg/day of L-ergothioneine, from about 15 to about 35 mg/day, preferably from about 20 to about 30 mg/day, and most preferably about 20 or about 25 mg/day. The dose is preferably administered as a single administration once per day, thus comprising 15-50 mg of L-ergothioneine, 15-35 mg of L-ergothioneine, 20-30 mg of L-ergothioneine, or 20 or 25 mg of L-ergothioneine. The most preferred form of the compound is free acid, and the foregoing doses are preferably based on the weight of the free acid.

(43) Dosage Forms/Routes of Administration

(44) Pharmaceutical compositions for preventing and/or treating a subject are further provided comprising a therapeutically effective amount of L-ergothioneine or a pharmaceutically acceptable salt or adduct thereof and one or more pharmaceutically acceptable excipients. A “pharmaceutically acceptable” excipient is one that is not biologically or otherwise undesirable, i.e., the material can be administered to a subject without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. The carrier can be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art. The carrier can be a solid, a liquid, or both.

(45) The disclosed compounds can be administered by any suitable route, preferably in the form of a unit dosage form adapted to such route, and in a dose effective for the treatment or prevention intended. For oral administration, the L-ergothioneine and other ingredients can be enclosed in a hard or soft-shell gelatin capsule, compressed into tablets, or incorporated directly into the individual's diet. Suitable dosage forms include ingestible tablets, buccal tablets, films, powder sachets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of the compositions and preparations can, of course, be varied and can conveniently be from about 5% to about 80% of the weight of the unit.

(46) Tablets, troches, pills, capsules, and the like can also contain the following: a binder, such as gum gragacanth, acacia, corn starch, or gelatin; excipients such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid, and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin, or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it can contain, in addition to materials of the above type, a liquid carrier. Various other materials can be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules can be coated with shellac, sugar, or both. A syrup or elixir can contain the agent, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye, and flavoring, such as cherry or orange flavor.

EXAMPLES

(47) In the following examples, efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.) but some errors and deviations should be accounted for. The following examples are put forth to provide those of ordinary skill in the art with a complete disclosure and description of how the methods claimed herein are made and evaluated and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention.

Example 1. Evaluation of the Antioxidant Effects of Compound L-ergothioneine in Normal Human Epidermal Keratinocytes Under Basal or UV-Irradiated Conditions

(48) In the present study, the effects of compound L-Ergothioneine were investigated in normal human epidermal keratinocytes (NHEK) under basal or UV-irradiated conditions. More specifically, the effects of this compound were evaluated using RT-qPCR technology. Extracted mRNA was analyzed using a PCR array (“mQPA-8-Nrf2”) for the analysis of 8 target genes (including 1 housekeeping gene) selected for their role in Nrf2 pathway. Prior to this assay, a preliminary cytotoxicity assay was performed on compound L-Ergothioneine and Resveratrol (reference in basal condition) using a standard WST-8 reduction assay, in order to determine the concentrations to be tested in this study.

(49) Abbreviations

(50) cDNA Complementary desoxyribonucleic acid

(51) DMSO Dimethyl sulfoxide

(52) DNA Desoxyribonucleic acid

(53) mQPA Marker qPCR array

(54) mRNA Messenger ribonucleic acid

(55) MW Molecular weight

(56) NHEK Normal human epidermal keratinocytes

(57) OD Optical density

(58) PBS Phosphate buffered saline

(59) RE Relative expression

(60) RIN RNA Integrity number

(61) RNA Ribonucleic acid

(62) RT Room temperature

(63) RT-qPCR Reverse transcription quantitative Polymerase chain reaction

(64) Sd Standard deviation

(65) sem Standard error of the mean

(66) SFM Serum free medium

(67) UV Ultraviolet

(68) WST-8 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt

(69) Materials and Methods

(70) Biological Model

(71) Cell type: Normal human epidermal keratinocytes (NHEK) used at the 3rd passage

(72) Culture conditions: 37° C., 5% CO2

(73) Culture medium: Keratinocyte-SFM optimized for the assay, supplemented with Epidermal

(74) Growth Factor Pituitary extract

(75) Assay medium: Keratinocyte-SFM optimized for the assay

(76) Test compound: L-Ergothioneine in ultrapure water

(77) Test concentrations: 0.5, 3 and 30 μM

(78) Reference: Resveratrol

(79) Test concentration: 20 μM

(80) Preliminary Cytotoxicity Assay

(81) Cell type: NHEK in assay medium

(82) Incubation time: 24 hours

(83) After treatment, the cells were incubated with WST-8 (highly water-soluble tetrazolium salt) reduced in a water-soluble orange colored product (formazan) by succinate dehydrogenase (mitochondrial enzyme). This transformation is proportional to the number of living cells and their metabolic activity. The optical density (OD) of the extracts at 450 nm was recorded with a spectrometer (VERSAmax, Molecular Devices).

(84) Keratinocytes were seeded in 24-well plates and cultured for 24 hours in culture medium and in assay medium for a further 24 hours. The medium was then replaced by assay medium containing or not (control) the compound or Resveratrol and cells were pre-incubated for 24 hours.

(85) After pre-incubation, the medium was then removed and replaced by a PBS solution. For basal conditions, the plate was kept in the dark during the irradiation time. For irradiated conditions, the cells were irradiated with UVB—275 mJ/cm.sup.2 (+UVA—2 J/cm.sup.2) using a SOL500 Sun Simulator equipped with an H2 filter (Dr. Hönle, AG). After irradiation time, the treatments were renewed, and the cells were incubated for 24 hours. All experimental conditions were performed in n=3. At the end of incubation, the cells were washed in phosphate buffered saline (PBS) solution and immediately frozen at −80° C.

(86) Differential Expression Analysis

(87) The expression of markers was analyzed using RT-qPCR method on total RNA extracted from the cell monolayers of each experimental condition (before RNA extraction, the replicates of the same experimental condition were pooled). The analysis of transcripts was performed in n=2 using a PCR array dedicated to research and adapted to ‘screening’ format and targeting 8 genes selected for their role in Nrf2 pathway.

(88) RNA Extraction and Reverse Transcription

(89) Total RNA was extracted from each sample using TriPure Isolation Reagent® according to the supplier's instructions. The amount and quality of RNA were evaluated using capillary electrophoresis (Bioanalyzer 2100, Agilent technologies). The complementary DNA (cDNA) was synthetized by reverse transcription of total RNA in presence of oligo(dT) and «Transcriptor Reverse Transcriptase» (Roche Molecular System Inc.). The cDNA quantities were then adjusted before PCR.

(90) Quantitative PCR

(91) The PCR (Polymerase Chain Reaction) were performed using the «LightCycler®» system (Roche Molecular System Inc.) according to the supplier's instructions. The reaction mix (10 μl final) was prepared as follows:

(92) 2.5 μl of cDNA,

(93) primers (forward and reverse),

(94) reagent mix (Roche) containing taq DNA polymerase, SYBR Green I and MgCl2.

(95) The incorporation of fluorescence in amplified DNA was continuously measured during the PCR cycles. This resulted in a “fluorescence intensity” versus “PCR cycle” plot allowing the evaluation of a relative expression (RE) value for each marker. The value selected for RE calculations is the “output point” (Ct) of the fluorescence curve. For a considered marker, the highest is the cycle number; the lowest is the mRNA quantity. The RE value was calculated with the formula: (½.sup.number of cycles)×10.sup.6. The PCR array used in the present study included 1 reference gene (RPS28).

RESULTS AND CONCLUSION

(96) Preliminary Cytotoxicity Assay

(97) The results of the preliminary cytotoxic assay are presented in Table 1.

(98) TABLE-US-00001 TABLE 1 Effect of compound L-Ergothioneine and Resveratrol on the viability of keratinocytes after 24 hours of incubation L-Ergothioneine   Unit: μM Stock solution prepared at 43611 μM in Ulltrapure water Control 2.2 6.7 20 60 180 540 1620 4860 Viability (%) 102 95 97 97 102 97 95 98 91 79 99 100 97 98 99 100 99 100 89 82 102 102 105 101 97 99 99 0 95 89 Mean (%) 100 100 99 99 99 97 66 92 83 sem (%) 1 3 1 1 1 1 33 2 3 Morphologicalobservations + + + + + + + + + Resveratrol   Unit: μM Stock solution prepared at 50 mM in DMSO Control 0.247 0.741 2.2 6.7 20 60 180 540 Viability (%) 103 96 101 102 109 109 97 65 32 8 109 99 98 100 105 108 93 67 32 8 101 91 99 99 105 101 88 64 29 8 Mean (%) 100 99 101 106 106 93 65 31 8 sem (%) 2 1 1 1 3 3 1 1 0 Morphologicalobservations + + + + + + * * −, * +: normal population; +/−: growth reduction; −: toxicity; 0: cell mortality g: grains of compound; op: opacity of the compound; *: morphological modification; ag: agglutinated cells
Effect on Gene Expression

(99) Gene expression results are presented in Tables 2-4.

(100) TABLE-US-00002 TABLE 2 Validation of the effect of UVB (+UVA) irradiation on gene expression profile of keratinocytes Irradiated condition UVB - 275 mJ/cm.sup.2 (+UVA -2 J/cm.sup.2) Genes Control- % Control mQPA-8-Nrf2 Abbreviation Cycles Cycles RPS28 Housekeeping RPS28 20.56 20.35 100 20.56 20.29 Oxidative and NQO1 32.77 32.10 101 cellular stress 32.09 32.18 response HMOX1 28.44 26.10 404 28.31 26.14 MT1G 26.16 27.53 34 26.16 27.43 TXN 19.35 19.61 79 19.38 19.34 TXNRD1 23.34 24.21 50 23.35 24.03 GCLC 26.15 26.95 43 25.79 26.89 GCLM 24.82 26.01 35 24.72 26.08

(101) TABLE-US-00003 TABLE 3 Effects of reference Resveratrol and compound L-Ergothioneine on gene expression profile of keratinocytes under basal conditions Resveratrol L-Ergothioneine Control 20 μM 0.5 μM 3 μM 30 μM — % Control % Control % Control % Control Cycles Cycles RPS28 Cycles RPS28 Cycles RPS28 Cycles RPS28 Housekeeping 20.56 20.69 100 20.48 100 20.33 100 20.53 100 20.56 20.91 20.49 20.47 20.36 Oxidative and  NQO1 32.77 28.76 1468 31.95 127 31.86 131 31.55 155 cellular stress 32.09 28.74 32.00 31.81 31.73 response HMOX1 28.44 26.35 451 28.50 86 28.54 91 28.24 98 28.31 26.53 28.54 28.19 28.33 MT1G 26.16 26.77 79 25.85 113 26.08 99 25.86 115 26.16 26.71 25.98 25.95 25.82 TXN 19.35 17.80 345 19.39 87 19.34 83 19.27 98 19.38 17.83 19.61 19.60 19.29 TXNRD1 23.34 21.35 492 23.76 75 23.65 72 23.52 82 23.35 21.22 23.63 23.67 23.52 GCLC 26.15 23.73 554 25.81 111 25.50 118 25.44 140 25.79 23.72 25.66 25.61 25.28 GCLM 24.82 22.14 736 24.77 95 24.66 97 24.65 98 24.72 22.11 24.78 24.64 24.70

(102) TABLE-US-00004 TABLE 4 Effects of compound L-Ergothioneine on gene expression profile of keratinocytes under UV-irradiated conditions Irradiated conditions: UVB - 275 mJ/cm.sup.2 (+UVA - 2 J/cm.sup.2) L-Ergothioneine 0.5 μM 3 μM 30 μM Control % Control % Control % Control mQPA-8-Nrf2 Cycles Cycles RPS28 Cycles RPS28 Cycles RPS28 Housekeeping 20.35 20.37 100 20.26 100 20.52 100 20.29 20.13 20.33 20.65 Oxidative and  NQO1 32.10 31.98 118 31.63 136 31.24 207 cellular stress 32.18 31.69 31.72 31.47 response HMOX1 26.10 25.94 104 26.05 109 25.92 141 26.14 26.05 25.90 25.85 MT1G 27.53 27.67 81 27.52 94 27.72 102 27.43 27.74 27.57 27.72 TXN 19.61 19.56 89 19.45 99 19.65 101 19.34 19.58 19.48 19.78 TXNRD1 24.21 24.14 99 24.15 97 24.07 120 24.03 23.99 24.13 24.16 GCLC 26.95 26.75 106 26.58 126 26.30 181 26.89 26.78 26.55 26.36 GCLM 26.01 26.49 76 26.23 86 26.47 86 26.08 26.24 26.24 26.57

(103) At the end of the culture and after a morphological observation of cells, it turned out that the viability of NHEK treated with resveratrol under irradiated condition was strongly impacted. The treatment of the NHEK with the reference compound, resveratrol, tested at 20 resulted in the stimulation of the expression of all genes (except MT1G) involved in oxidative and cellular stress response: NQO1, HMOX1, TXN, TXNRD1, GCLC and GCLM. These results were expected and validated the assay.

(104) Under the experimental conditions of the assay, compound L-Ergothioneine, tested at 0.5, 3 and 30 μM did not induce major modulations on the gene expression profile of basal keratinocytes. At the highest tested concentration (30 compound L-Ergothioneine only slightly increased (140% of the control) the expression of GCLC (Glutamate-cysteine ligase, catalytic subunit). At the lowest tested concentrations, no effect was observed.

(105) The UVB (+UVA) irradiation at 275 mJ/cm.sup.2 (+2 J/cm.sup.2) resulted in a clear modulation of the gene expression profile of normal human epidermal keratinocytes (NHEK). More specifically, the irradiation mainly induced an up-regulation of a marker of the early oxidative stress response (HMOX1 involved in the first response to oxidative stress), and a down-regulation of the expression of genes involved in oxidative and cellular stress response (MT1G, TXNRD1, GCLC and GCLM). Under the experimental conditions of the assay, compound L-Ergothioneine, tested at 0.5, 3 and 30 did not induce major modulations on the gene expression profile of irradiated keratinocytes. At the highest tested concentration (30 compound L-Ergothioneine only slightly increased the expression of GCLC (181% of the stimulated control) and in a lesser extent HMOX1 (141% of the stimulated control). At the lowest tested concentrations, no effect was observed.

Example 2. Effects of Oral L-ergothioneine (25 mg/Day) on Plasma Glutathione in Healthy Humans

(106) Protocol Synopsis

(107) Title of Study:

(108) Effects of Oral L-Ergothioneine on Plasma Glutathione

(109) Study Period:

(110) 4 weeks

(111) Test Product:

(112) L-Ergothionine 25 mg/capsule (consumed once daily for 30 days with other supplements or at main meal)

(113) Comparator Products:

(114) Glutathione (1400 mg) adminstered IV once per week and S-acetyl-glutathione (200 mg;) adminstered orally once daily

(115) Objectives:

(116) 1. To demonstrate the tolerability of oral administration of 25 mg ergothioneine

(117) 2. To demonstrate the ability of oral administration of 25 mg ergothioneine to increase plasma GSH

(118) Design:

(119) Following enrollment, subjects will be randomly assigned to either receive one IV of glutathione, 1400 mg, once weekly for four weeks, 5-acetyl glutathione, 200 mg a day for four weeks, or L-ergothioneine, once daily for four weeks. A Baseline will be established looking at Total and Percent Reduced Glutathione. These same values will be measured at the end of the four weeks. Subjects will be contacted once a week while in the study for an assessment of compliance with intervention.
Study Population:
Male and female subjects 25-75 years of age
Number of Subjects:
5, assigned as follows: 1 subject will receive the GSH administered once weekly for 4 weeks; 1 subject will receive S-acetyl-glutathione once daily for 4 weeks; 3 subjects will receive L-ergothioneine once daily for 4 weeks
Inclusion Criteria:
1. Individuals must be between 25-70 years of age with no known medical conditions that, in the investigator's opinion, may interfere with study participation.
2. Subjects must present with mild to moderate signs oxidative stress or inflammation.
3. Willingness to cooperate and participate by following Study requirements.
4. Individuals must sign informed consent, photo release consent and confidentiality agreement.
Exclusion Criteria:
1. Any Individuals that are being treated for cancer or have cancer.
2. Individuals currently taking certain medications or any dietary supplements, which in the opinion of the investigator might interfere with the study. This would include but not be limited to routine high dosage use of anti-inflammatory drugs (aspirin, ibuprofen, corticosteroids) immunosuppressive drugs or antihistamine medications), and insulin, anti-hypertensive drugs, and especially antioxidants.
3. Individuals with uncontrolled metabolic diseases such as diabetes (Type I and II), hypertension, hyperthyroidism or hypothyroidism, severe chronic asthma, immunological disorders such as HIV positive, AIDS and systemic lupus erythematosus or mastectomy for cancer involving removal of lymph nodes.
4. Women known to be pregnant, nursing or planning to become pregnant.
5. Individuals participating in other clinical studies evaluating antioxidants or anti-inflammatory interventions.

RESULTS AND CONCLUSIONS

(120) Study results are depicted in the FIGURE.

(121) Subjects received 25 mg L-ergothioneine or 200 mg S-acetyl-glutathione (SAG; comparator intervention) for 1 month. The one subject who was received GSH iv contracted Covid-19 during the study, and did not complete the study. No data are provided for this single subject. No adverse events were reported, and compliance L-ergothioneine and SAG was excellent, based on the counting of test materials at the end of the study.

(122) The 3 study subjects that received L-ergothioneine 25 mg daily po had different levels of total GSH at baseline, ranging from 353 μM to 584 μM. The single subject taking the comparator, SAG, had a baseline level of total GSH of 727 μM. The three study subjects that received L-ergothioneine 25 mg daily po all exhibited increased levels of total GSH at Day 30, ranging from 502 μM to 867 μM. The single study subject that received the comparator intervention, SAG, showed a reduction in total GSH of 547 μM. The % change from baseline through Day 30 of three study subjects that received L-ergothioneine ranged from 13% (IB) to 146% (ST). The % change from baseline of the study subject that received SAG was −25%.

(123) Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.